Evidence mapPaperPMID 34792863Full record

Observational studyAnnals of clinical and translational neurology2021

Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study.

Friedemann Paul, Peter A Calabresi, Frederik Barkhof, Ari J Green, Randy Kardon, Jaume Sastre-Garriga, Sven Schippling, Patrick Vermersch, Shiv Saidha, Bianca S Gerendas and 5 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 8 countries.

Friedemann PaulNeuroCure Clinical Research Center and Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-6378-0070
Peter A CalabresiDepartment of Neurology, Johns Hopkins Hospital, Baltimore, Maryland, USA.ORCID 0000-0002-7776-6472
Frederik BarkhofDepartment of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands.
Ari J GreenDepartment of Neurology, Multiple Sclerosis Center, University of California San Francisco, San Francisco, Califonia, USA.
Randy KardonIowa City VA Center for Prevention and Treatment of Visual Loss, Department of Veterans Affairs Hospital Iowa City, University of Iowa Hospital and Clinics, Iowa City, Iowa, USA.
Jaume Sastre-GarrigaDepartment of Neurology/Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sven SchipplingNeuroimmunology and Multiple Sclerosis Research Section, University Hospital Zurich, Zurich, Switzerland.
Patrick VermerschUniv. Lille, Inserm UMR1172 LilNCog, FHU Precise, Lille, France.
Shiv SaidhaDepartment of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.
Bianca S GerendasDepartment of Ophthalmology, Vienna Reading Center, Medical University of Vienna, Vienna, Austria.
Ursula Schmidt-ErfurthDepartment of Ophthalmology, Medical University of Vienna, Vienna, Austria.
Catherine AgoropoulouNovartis Pharma AG, Basel, Switzerland.
Ying ZhangNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Gustavo SeiferNovartis Pharma AG, Basel, Switzerland.
Axel PetzoldMoorfields Eye Hospital, The National Hospital for Neurology and Neurosurgery, London, UK.ORCID 0000-0002-0344-9749
Medical University of Vienna · ATNovartis (Switzerland) · CHAmsterdam University Medical Centers · NLInserm · FRJohns Hopkins Hospital · USJohns Hopkins University · USMax Delbrück Center · DEMoorfields Eye Hospital · GBNovartis (United States) · USUniversitat Autònoma de Barcelona · ESUniversity Hospital of Zurich · CHUniversity of California, San Francisco · USUniversity of Iowa · US

Funding

Novartis Pharma
6 · The paper itself

Abstract

objectiveTo evaluate changes over 3 years in the thickness of inner retinal layers including the peripapillary retinal nerve fiber layer (pRNFL), and combined macular ganglion cell and inner plexiform layers (mGCIPL), in individuals with relapsing-remitting multiple sclerosis (RRMS) versus healthy controls; to determine whether optical coherence tomography (OCT) is sufficiently sensitive and reproducible to detect small degrees of neuroaxonal loss over time that correlate with changes in brain volume and disability progression as measured by the Expanded Disability Status Scale (EDSS).

methodsIndividuals with RRMS from 28 centers (n = 333) were matched with 64 healthy participants. OCT scans were performed on Heidelberg Spectralis machines (at baseline; 1 month; 6 months; 6-monthly thereafter).

resultsOCT measurements were highly reproducible between baseline and 1 month (intraclass correlation coefficient >0.98). Significant inner retinal layer thinning was observed in individuals with multiple sclerosis (MS) compared with controls regardless of previous MS-associated optic neuritis--group differences (95% CI) over 3 years: pRNFL: -1.86 (-2.54, -1.17) µm; mGCIPL: -2.03 (-2.78, -1.28) µm (both p < 0.0001; effect sizes 0.39 and 0.34). Greater inner retinal layer atrophy was observed in individuals diagnosed with RRMS <3 years versus >5 years (pRNFL: p < 0.05; mGCIPL: p < 0.01). Brain volume decreased by 1.3% in individuals with MS over 3 years compared to 0.5% in control subjects (effect size 0.76). mGCIPL atrophy correlated with brain atrophy (p < 0.0001). There was no correlation of OCT data with disability progression.

interpretationOCT has potential to estimate rates of neurodegeneration in the retina and brain. The effect size for OCT, smaller than for magnetic resonance imaging based on Heidelberg Spectralis data acquired in this study, was increased in early disease.

Indexed as

AdultAtrophyBrainFemaleHumansMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingProspective StudiesRetinaTomography, Optical Coherence

Identifiers

PMID34792863
PMCPMC8670323
OpenAlexW3212182683

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.